News & Events
CPRIT encourages Texans to apply for national ARPA-H Program Manager
This year, the federal government established the Advanced Research Projects Agency for Health (ARPA-H), a new agency to catalyze transformative high-risk, high-reward research to drive biomedical and health breakthroughs that will transform medicine and health for the benefit of all patients and that cannot readily be accomplished through traditional research or commercial activity.
President Biden recently named Dr. Renee Wegrzyn as the first director of the agency. A home site for the agency has not yet been determined.
State cancer agency approves $49 million in new research grants
(AUSTIN) Today, the Oversight Committee of the Cancer Prevention and Research Institute of Texas (CPRIT), held a special meeting to approve a slate of awards totaling $48,923,075 for cancer research and product development. The list of grants is included at the bottom of this release.
“Today, the CPRIT Oversight Committee raised the bar on the fight against cancer,” said CPRIT CEO Wayne Roberts. “These grants continue to fund the path forward for cancer research in the state of Texas and provide vital financial support for the researchers, labs and institutions on the frontline of this monumental statewide effort to end cancer as we know it.”
The CPRIT Innovations Conference VI Returns in 2023
CPRIT is proud to announce our Innovations in Cancer Prevention and Research Conference VI returns in-person October 2 - 3, 2023 at Moody Gardens Hotel, Spa and Convention Center in beautiful Galveston, Texas. (more)
CPRIT Releases Four Product Development Research Funding Opportunities (Cycle 23.1 RFAs)
CPRIT announces the release of four (4) Requests for Applications (RFAs) for FY 2023 Product Development Research grants. Complete RFAs and instructions are available in the “Apply for Funding” section of CPRIT’s website.
• Texas Therapeutics Company Product Development Research Award (TTC)
• Texas Diagnostics and Devices Company Product Development Research Award (TDDC)
• Texas New Technologies Company Product Development Research Award (TNTC)
• Seed Awards for Product Development Research (SEED)
CPRIT Oversight Committee approves over $89 million in grants
(AUSTIN) Today, in a meeting at the State Capitol, the Oversight Committee of the Cancer Prevention and Research Institute of Texas (CPRIT), approved a large slate of awards totaling over $89 million for cancer research, prevention and product development. The list of grants is included below.
“The awards approved today by the Oversight Committee illustrate the depth and breadth of CPRIT's impact in the Texas fight against cancer,” said CPRIT CEO Wayne Roberts. “From recruitment grants bringing the brightest cancer researchers to Texas, to supporting lifesaving prevention programs across the state and providing critical investments in developing new cancer-fighting drugs, CPRIT touched all the bases for a home run against cancer.”
CPRIT CEO Roberts Endorses Bertagnolli NCI Appointment
Last week, President Biden nominated Dr. Monica Bertagnolli to lead the National Cancer Institute. An accomplished surgical oncologist and scientist, Dr. Bertagnolli is the first woman to hold this post.
As NCI and CPRIT are the top two public funders of cancer research in the world, CPRIT CEO Wayne Roberts has sent the White House an official letter to add his voice to those supporting Dr. Bertagnolli's nomination.
Our Grantees in the News
Healthy women have cells that resemble breast cancer, study finds
Transfer RNA regulates messenger RNA degradation
TAMEST Member Profile: Sharon Y.R. Dent, Ph.D. (NAS), MD Anderson Cancer Center
Center for Nanoscale Imaging Sciences’ inaugural workshop unites national experts to advance imaging across scales
MD Anderson Research Highlights for November 21, 2024
Postdoc Zhang honored among ‘35 Innovators Under 35’
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
Perimeter B-Series OCT with ImgAssist AI 2.0 Demonstrates Super-Superiority Compared to Standard-of-Care in Pivotal Clinical Trial
Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases
Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic
Healthy Women May Have Aneuploid Epithelial Cells Resembling Breast Cancer
Next-generation sequencing in ocular oncology brings advances in diagnosis, management
MD Anderson, the Oden Institute and TACC announce funding for six new collaborative cancer projects
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference
Rice collaborators host inaugural convening to promote advancement of global cancer detection efforts
New imaging platform developed by Rice researchers revolutionizes 3D visualization of cellular structures
CAR T cells armed with IL-15 show promise in treating solid cancers
Advances in small cell lung cancer classification
Baylor and Rice researchers target bone metastases in breast cancer with $2.3M grant
Dr. Patricia Chalela Named IBC Foundation Endowed Professorship in Health Promotion Research
2 UT Health SA scientists awarded grants for innovative cancer research
Molecular Biologist Receives TAMEST O’Donnell Award
Drs. Brenner, Rooney named National Academy of Inventors Fellows
New open-source platform supports large imaging data analysis
FunMap reveals a functional network of genes and proteins in human cancer
Exploring the Future of Digital Twins in Oncology: Highlights from the JCCO Retreat
Repurposed drug has promising efficacy in non-small cell lung cancer
Daniel Siegwart, Ph.D., named fellow of the National Academy of Inventors
Real expectations in treating pancreatic cancer – and the power to prevent it
Greehey CCRI Deputy Director, Manjeet Rao, PhD, to receive $100K”The Cure Starts Now” Grant.
Luiz Penalva, PhD, to Receive “The Cure Starts Here” Grant.
SPACe: A new open-source platform that supports large imaging data analysis on standard computers
Indapta Therapeutics Announces Clinical Study Collaboration With Sanofi on Multiple Myeloma Program
Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium
Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 in Combination with KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study
Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)
Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price Requirements
Perimeter Provides Update on Canada Postal Strike and Mailing of the Company's 2024 Annual General Meeting Materials
Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium
2 Houston professors named as fellows for prestigious group of inventors
Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits
UTA researcher named National Academy of Inventors fellow
Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium
TAMEST Names Gerta Hoxhaj, Ph.D., of Children’s Medical Center Research Institute at UT Southwestern, as Recipient of 2025 Mary Beth Maddox Award and Lectureship
CRI’s Gerta Hoxhaj, Ph.D., named TAMEST 2025 Mary Beth Maddox Award and Lectureship recipient
FROM THE LABS: Mapping functional relations among proteins and genes helps illuminate their role in cancer
New Rice-TMC research projects drive advances in health and medicine
Indapta Therapeutics Secures $22.5 Million to Advance Clinical Trials of Innovative Cancer and Autoimmune Treatments
Indapta Therapeutics lands $22.5 million for cancer-fighting clinical trials (PDF)
Dr. Amelie Ramirez Addresses Latino Cancer, Prevention at San Antonio Breast Cancer Symposium
March Biosciences Elects Peter Olagunju as Chair of Board of Directors
MD Anderson Research Highlights for December 18, 2024
Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma
Marker Therapeutics Announces $16.1 Million Private Placement
New molecule-creation method a ‘powerful tool’ to accelerate drug synthesis and discovery
Houston Methodist scientists make surprising discovery pinpointing when good cholesterol becomes harmful
Cell Source Presents Potential Breakthrough in the Development of Off-the-Shelf CAR-T Cell Therapy at American Society of Hematology Annual Meeting
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024
11 new research advances from the past year
Rice chemists create eco-friendly method to make chlorine-based materials for drugs and chemicals
CRI scientists link hematopoietic cell transplant deaths to beta-blocker use
Patients with heart disease may be at increased risk for advanced breast cancer
Gradalis’ GRAD1405 bi-shRNAi Candidate First to Show Positive Impact on Three Key KRAS Mutations Identified in Drug Resistant Lung, Colon and Pancreatic Cancers
Stimulating fat cells with GIP receptor has potential to treat obesity
FROM THE LABS: Image of the Month: Astrocytes, neurons and memory
Biomedical Engineering Symposium reveals how rapid advances in technology are transforming medicine
Devising a brilliant biomedical idea within an hour
Dr. Amelie G. Ramirez Explores Health Promotion for McGovern Award Lecture
MD Anderson Research Highlights for January 9, 2025
Committed to making cervical cancer screening easier
ZIC1 gene drives distinct medulloblastoma types in different ways
Industry veteran Dr. Yan Moore joins Allterum Therapeutics as CEO to advance clinical program in ALL
CTMC and Syenex Launch Partnership to Accelerate Scalability of Cell Therapies (PDF)
Leading cancer clinician, researcher Dr. Jenny Chang to lead Houston Methodist Academic Institute
Chances of quitting smoking improve with integrated care, including medication and counseling
New book provides big recommendations from the Advancing the Science of Cancer in Latinos Conference
Advancing the Science of Cancer in Latinos: 2024 Conference Proceedings
Elevating the Research and Treatment Needs of Latino Children, Adolescents, and Young Adult Survivors
Novel Immunotherapy Trials May Drive Progress in Kidney Cancer Field
A new e-book from UT Health San Antonio offers recommendations on research about cancer in Latinos
UTHealth Houston research: Children born to young men with cancer have slight increases in preterm birth, low-birth-weight children, but not birth defects
UT Southwestern pharmacologists earn Hill Prize from TAMEST
Inside UT Health San Antonio's roadmap for Latino cancer care
All for Them Showcases Program Impacts at Major Conferences
‘Faster than others could ever dream’: Venture studio accelerates biotech innovation to transform patient care
New interdisciplinary research lays groundwork for predicting if bone cancer will spread
UT Health San Antonio, UTSA researchers receive prestigious 2025 Hill Prizes for medicine and technology
National Research Mentoring Network – Resource Center at UNTHSC receives prestigious Presidential Award
President’s Lecture Series: Using nanotechnology to deliver genetic medicines
MD Anderson Research Highlights for January 22, 2025
Targeting potassium channel shows promise for treating brain tumours
DNA and Histone Methylation Keeps Rowdy Retrotransposons Quiet When Recovering from Injury
Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer
Innovators Join Texas Medical Center’s 2025 Accelerator for Cancer Therapeutics (ACT) to Advance Oncology Treatment in Texas
March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR-T Cell Therapy, for T-Cell Lymphoma
Study reveals biomarker for high risk of metastasis
Rice SynthX and MD Anderson Team Awarded Kleberg Medical Grant for Brain Metastasis Research
UTRGV School of Medicine cancer researcher explains importance of preventive care to one of RGV’s most common cancers
Dr. Amelie Ramirez Addresses Latino Childhood Obesity in Telemundo Special
From bench to bedside and back: CAR T cells armed with IL-15 show promise in treating solid cancers
UTRGV School of Medicine hosts community event to promote awareness and prevention of cervical cancer
‘Pushing the boundaries of radiation treatment’: Breakthrough in pancreatic cancer therapy advances to clinical trials
How are Antibody-Drug Conjugates Shaping the NSCLC Treatment Paradigm? With David Gerber, MD
Ypsilon Receives $2.7 Million Non-Dilutive Grant to Advance Next-Generation TCRm Antibodies
Houston Methodist researchers identify inhibitor drugs to treat aggressive breast cancer
ASCO Congratulates 2025 Special Awards Recipients
The Rose Secures $2.5 Million CPRIT Grant to Expand Life-Saving Breast Cancer Prevention Services to Women in Rural Texas
UTRGV study finds the Valley has the highest rate of cervical cancer in the U.S.
Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers
4 questions with immunology researcher Susan Bullman
Study reveals cellular recycling process key to human health
Curtana Pharmaceuticals Announces Breakthrough in Pediatric Brain Cancer Treatment with Dual Studies Published in Nature Communications (PDF)
Rice researchers discover new way to customize living materials for tissue engineering, drug delivery and 3D printing
Baylor Chemist John L. Wood, Ph.D., Designated University Distinguished Professor
Gradalis Secures FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Vigil® (Gemogenovatucel-T): An Investigational Personalized Immunotherapy for Advanced Ovarian Cancer
Childhood brain cancer research breakthrough could transform treatment, international study finds
Texas A&M University: Excellence in chemistry research and learning
Kurmasheva Lab to be Featured in CPRIT Annual Report
MD Anderson Research Highlights for February 10, 2025
Sprinter and marathoner CAR T cells reveal their distinct cancer-killing behavior
Rice researchers discover new way to customize living materials for tissue engineering, drug delivery and 3D printing
New Leadership at Texas Children's Cancer & Hematology Center: Continuing a Legacy of World-Class Care and Innovation
Antibody designed to fight immunotherapy-resistant cancers
Three Texas A&M Professors Elected To National Academy Of Engineering
UTRGV research conference covers disparities in cancer research, treatment
Long-term survival following CAR T cell therapy to treat neuroblastoma
Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program
CHRISTUS St. Vincent First in New Mexico to Bring Perimeter Medical Imaging AI's Pioneering Technology to Surgery
Media Contact
Mark Loeffler
Communications Director
Phone: 512-305-8483
Email: mloeffler@cprit.texas.gov